Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Merck's Fosamax

Executive Summary

Merck's Fosamax: Wyeth-Ayerst and Merck enter into a co-promotion agreement under which Wyeth would promote the osteoporosis treatment to U.S. obstetricians and gynecologists when the agent is approved by FDA, Merck announces June 19. Merck would market the product to other key specialty groups such as endocrinologists, rheumatologists and primary care physicians. The Fosamax (alendronate) NDA will be reviewed by an FDA advisory committee on July 13 ("The Pink Sheet" June 19, T&G-6)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026412

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel